Building access to the Regenstrief Institute is restricted at least through April 6, 2020. More on our coronavirus precautions.
Building access is restricted through 4/6. Learn more.
Patient on life support in ICU

A new study shows that critically ill patients are not benefitting from antipsychotic medications that doctors have been using to treat delirium in patients in intensive care units. The evidence suggests doctors may need to re-examine the practice. Regenstrief investigator Babar Khan, M.D., was a co-author on the study.

Each year, more than seven million hospitalized patients in the United States develop delirium. The acute brain failure results in confusion and long-term memory problems.

The large study, MIND-USA (Modifying the INcidence of Delirium), sought to answer whether typical and atypical antipsychotics — haloperidol or ziprasidone — affected delirium, survival, length of stay or safety in ICU patients. Researchers screened nearly 21,000 patients at 16 U.S. medical centers. Of the 1,183 patients on mechanical ventilation or in shock, 566 became delirious and were randomized into groups receiving either intravenous haloperidol, ziprasidone or placebo (saline). Results showed that patients who received the drugs did not experience any improvements whatsoever in delirium, coma, length of stay or survival.

Study authors say the medicines are bringing risk and cost without benefit, based on the outcomes measured in this study. Doctors have been prescribing the drugs for 40 years.

Dr. Khan, who worked on this study, has conducted extensive studies on treating and preventing delirium. He led a project at Regenstrief that developed and validated the Confusion Assessment Method for the Intensive Care Unit 7. It’s an easy-to-use method to determine the severity of delirium.

The MIND-USA study was published in the New England Journal of Medicine. It was funded by the National Institute on Aging.

Related News

Mar 25, 2020 • News
More than 600 international registrations for Regenstrief specialized virtual conference to address coronavirus outbreak
LOINC®, an international health data standard maintained at Regenstrief Institute, is hosting a special public meeting to address the coronavirus pandemic. More than 600 people from around the world are signed up to attend the virtual event on March 26 related to LOINC coding for SARS-CoV-2/COVID-19. In response to the coronavirus pandemic, LOINC has created…
Continue Reading >
Mar 18, 2020 • News
LOINC team actively working to expand tracking codes for coronavirus
With the coronavirus now a pandemic, the LOINC team at Regenstrief is working continuously to create new codes to help public health officials around the globe track cases of the virus. Coordinating with the U.S. Centers for Disease Control and Prevention (CDC), public health and reference labs, and in vitro diagnostic manufacturers, the team has…
Continue Reading >